🇺🇸
HANGZHOU, China, SHANGHAI and TOKYO, Nov. 4, 2026 /PRNewswire/ — Minghui Pharmaceutical (“Minghui”) and ASKA Pharmaceutical Co., Ltd. (“ASKA”) today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan. MHB018A…
Source: prnewswire
Country: United States